Heparanase cooperates with Ras to drive breast and skin tumorigenesis

Cancer Research

Volumn 74, Issue 16, 2014, Pages 4504-4514

  Boyango, Ilanit ^a   Barash, Uri ^a   Naroditsky, Inna ^b   Li, Jin Ping ^c   Hammond, Edward ^d   Ilan, Neta ^a   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Department of Pathology Rambam Health Care Campus ^*  (Israel)

^c UPPSALA UNIVERSITY   (Sweden)

^d Progen Pharmaceuticals Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; HEPARANASE;

ANIMAL; BREAST TUMOR; C57BL MOUSE; CARCINOGENESIS; CELL GROWTH; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SCID MOUSE; SKIN TUMOR; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENES, RAS; GLUCURONIDASE; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; PHOSPHORYLATION; SKIN NEOPLASMS;

EID: 84905980623     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2962     Document Type: Article

References (58)

1. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010;277:3890-903.
2. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Intl J Biochem Cell Biol 2006;38:2018-39. (Pubitemid 44397619)
3. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-108.
4. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-7. (Pubitemid 32730777)
5. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009;34:511-9.
6. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011;30:253-68.
7. Vreys V, David G.Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-52. (Pubitemid 47153456)
8. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012;5:115-32.
9. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011;104:635-42.
10. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011;17:1382-93.
11. Barash U, Cohen-Kaplan V, Arvatz G, Gingis-Velitski S, Levy-Adam F, Nativ O, et al. A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 2010;24:1239-48.
12. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Intl J Cancer 2006;118:1609-17. (Pubitemid 43376422)
13. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005;105:1303-9. (Pubitemid 40170907)
14. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006;66:1455 -63.
15. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008;14:668-76. (Pubitemid 351231146)
16. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006;12:5471-80. (Pubitemid 44497263)
17. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, et al. Structure-function approach identi fies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 2009;69:1758-67.
18. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117:2249- 58.
19. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007;9:961-9. (Pubitemid 47190451)
20. Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, et al. Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases. Cancer Biol Ther 2013;14:417-27.
21. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 2008;68:10077-85.
22. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68. (Pubitemid 36677560)
23. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004;279:23536-41. (Pubitemid 38685666)
24. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PloS ONE 2009;4:e5181.
25. Zcharia E, Metzger S, Chajek-ShaulL T, Aingorn H, Elikn M, Friedmann Y, et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004;18:252-63. (Pubitemid 38186244)
26. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Intl J Cancer 2008;123:2566-73.
27. Arvatz G, Barash U, Nativ O, Ilan N, Vlodavsky I. Post-transcriptional regulation of heparanase gene expression by a 30 AU-rich element. FASEB J 2011;24:4969-76.
28. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007;361:829-34. (Pubitemid 47259014)
29. Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of Heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem 2013;288:12366-75.
30. Miller FR. Xenograft models of premalignant breast disease. J Mammary Gland Biology Neoplasia 2000;5:379-91. (Pubitemid 32236769)
31. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996;148:313-9.
32. Schwarz M, Munzel PA, Braeuning A. Non-melanoma skin cancer in mouse and man. Arch Toxicol 2013;87:783-98.
33. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005;4:908-13. (Pubitemid 41359756)
34. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A 2004;101:13613-7. (Pubitemid 39238451)
35. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, et al. Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical signi ficance in head and neck cancer. J Biol Chem 2012;287:6668-78.
36. Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N, et al. Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod Pathol 2009;22:1548-54.
37. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000;157:1167-75.
38. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
39. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013;342:1234850.
40. Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012;22:194-207.
41. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
43. Mueller MM. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 2006;42:735-44.
44. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011;121:1709-21.
45. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoformsin cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011;11:185-99.
46. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-94. (Pubitemid 46480971)
47. Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res 2014;74:412-9.
48. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007;5:195-201. (Pubitemid 46424000)
49. Ma Y, Guo FC, Wang W, Shi HS, Li D, Wang YS. Kras gene mutation as a predictor of cancer cell responsiveness to metformin. Mol Med Rep 2013;8:763-8.
50. Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE, et al. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther 2013;12:1190-201.
51. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65. (Pubitemid 37328850)
52. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014;25:91-101.
53. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003;63:8749-56. (Pubitemid 38064053)
54. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007;109:4914-23. (Pubitemid 46827789)
55. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011;15:1013-31.
56. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, et al. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 2013;280:2294-2306.
57. Sanderson RD, Iozzo RV. Targeting heparanase for cancer therapy at the tumor-matrix interface. Matrix Biol 2012;31:283-4.
58. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. New England J Med 2012;366:207-15.